Aarkstore - Glycogen Synthase Kinase 3 (GSK-3) Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Glycogen Synthase Kinase 3 (GSK-3) Inhibitors -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0eb0-YjgzM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Glycogen Synthase Kinase 3 (GSK-3) Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,Glycogen Synthase Kinase 3 (GSK-3) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Glycogen Synthase Kinase 3 (GSK-3) Inhibitors – PowerPoint PPT presentation

Number of Views:16

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Glycogen Synthase Kinase 3 (GSK-3) Inhibitors -Pipeline Insights, 2014


1
Glycogen Synthase Kinase 3 (GSK-3) Inhibitors
-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/73732/glycogen-synthase-kinase-3-gsk-3-inhibitor
    s-pipeline-insights-2014

2
Summary
  • DelveInsights,Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA). A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors. This report provides information on
    the therapeutic development based on the Glycogen
    Synthase Kinase 3 (GSK-3) Inhibitors dealing with
    mechanism of action, comparative analysis at
    various stages covering Filed, Phase III, Phase
    II, Phase I, IND filed, Preclinical, Discovery
    and unknown stages, therapeutics assessment by
    monotherapy and combination products and molecule
    type drug information. The report also covers the
    companies information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant
    products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Glycogen Synthase Kinase
    3 (GSK-3) InhibitorsThe report provides pipeline
    products under drug profile section which
    includes product description, MOA, licensors
    collaborators, development partner and chemical
    informationCoverage of the Glycogen Synthase
    Kinase 3 (GSK-3) Inhibitors pipeline on the basis
    of target, MOA, route of administration,
    technology involved and molecule typeThe report
    reviews key players involved in the therapeutics
    development for Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors and also provide company
    profilingThe report also gives the information
    of dormant and discontinued pipeline
    projects Pipeline products coverage based on
    various stages of development ranging from
    preregistration till discovery and undisclosed
    stages Provides pipeline assessment by
    monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete MOA intelligence and
    complete understanding over therapeutics
    development for Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors
  • Identify the relationship between the drugs and
    use it for target finding, drug repurposing, and
    precision medicine.
  • Devise corrective measures for pipeline projects
    by understanding Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors pipeline depth and focus of
    Indication therapeutics
  • Developing strategic initiatives to support your
    drug development activities.
  • Optimize your portfolio and keep you in touch
    with the rapidly changing pharmaceutical markets,
    and make the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies
  • Modify the therapeutic portfolio by identifying
    discontinued projects and understanding the
    factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive
    Landscape for Evidence based Decisions
  • You can order full Report with TOC and for Sample
    page visit _at_http//www.aarkstore.com/pharmaceutic
    als-healthcare/73732/glycogen-synthase-kinase-3-gs
    k-3-inhibitors-pipeline-insights-2014

7
Table of Content
  • Glycogen Synthase Kinase 3 (GSK-3) Inhibitors
    OverviewGlycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Disease AssociatedGlycogen Synthase
    Kinase 3 (GSK-3) Inhibitors Pipeline
    TherapeuticsGlycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Therapeutics under Development by
    Companies Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Late Stage Products (Filed and Phase
    III)Comparative Analysis Glycogen Synthase
    Kinase 3 (GSK-3) Inhibitors Mid Clinical Stage
    Products (Phase II)Comparative
    Analysis Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Early Clinical Stage Products (Phase I
    and IND Filed)Comparative Analysis Glycogen
    Synthase Kinase 3 (GSK-3) Inhibitors Discovery
    and Pre-Clinical Stage Products Comparative
    Analysis Drug Candidate Profiles

8
Table of Content
  • Glycogen Synthase Kinase 3 (GSK-3) Inhibitors
    Therapeutics Assessment Assessment by
    Monotherapy Products Assessment by Combination
    Products Assessment by Route of
    Administration Assessment by Molecule
    Type Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Discontinued Products Glycogen
    Synthase Kinase 3 (GSK-3) Inhibitors Dormant
    ProductsCompanies Involved in Therapeutics
    Development for Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors Appendix Methodology Contact
    Us Disclaimer

9
List of Tables
  • Number of Products under Development for Glycogen
    Synthase Kinase 3 (GSK-3) Inhibitors by Therapy
    Area, 2014Number of Products under Development
    for Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors, 2014Number of Products under
    Development by Companies Comparative Analysis by
    Late Clinical Stage Products (Filed and Phase
    III), 2014Comparative Analysis Mid Clinical
    Stage Products (Phase II), 2014Comparative
    Analysis Early Clinical Stage Products (Phase I
    and IND Filed), 2014Comparative Analysis
    Discovery and Pre-Clinical Stage Products,
    2014Drug Candidates Profiles 

10
List of Tables
  • Glycogen Synthase Kinase 3 (GSK-3) Inhibitors
    Assessment by Monotherapy Products Glycogen
    Synthase Kinase 3 (GSK-3) Inhibitors Assessment
    by Combination Products Glycogen Synthase Kinase
    3 (GSK-3) Inhibitors Assessment by Route of
    Administration Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors Assessment by Stage and Route
    of Administration Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors Assessment by Molecule
    Type Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Assessment by Stage and Molecule
    Type Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Therapeutics Discontinued
    Products Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Therapeutics Dormant ProductsProducts
    under Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for Glycogen
    Synthase Kinase 3 (GSK-3) Inhibitors by Therapy
    Area, 2014Number of Products under Development
    for Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors, 2014Late Clinical Stage Products
    (Filed and Phase III), 2014Mid Clinical Stage
    Products (Phase II), 2014Early Clinical Stage
    Products (Phase I and IND Filed), 2014Discovery
    and Pre-Clinical Stage Products, 2014Glycogen
    Synthase Kinase 3 (GSK-3) Inhibitors Assessment
    by Monotherapy Products Glycogen Synthase Kinase
    3 (GSK-3) Inhibitors Assessment by Combination
    Products Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Assessment by Route of
    Administration Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors Assessment by Stage and Route
    of Administration Glycogen Synthase Kinase 3
    (GSK-3) Inhibitors Assessment by Molecule
    Type Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors Assessment by Stage and Molecule Type

12
Related Reports
  • 2015 Worldwide Medical Laboratories
    Industry-Industry Market Report
  • 2015 Worldwide Pharmaceutical Preparation Mfg.
    Industry-Industry Market Report
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Glycogen Synthase Kinase 3 (GSK-3) Inhibitors
    -Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Glycogen Synthase Kinase 3 (GSK-3)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA).

    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com